ADAM15, ADAM metallopeptidase domain 15, 8751

N. diseases: 59; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE Strong ADAM15 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal stage and resection margin. 28282546 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE The knockdown of ADAM15 in a human xenograft model of bladder cancer inhibited tumor growth by 45% compared to controls. 26930657 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE ADAM15 to α5β1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. 21190186 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE Expression of ADAM8 and ADAM15 correlated significantly with tumour stage (P=0.048 and P=0.044), and ADAM12 expression correlated with tumour grade (P=0.011). 22677901 2012
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE Using human tumor and cDNA microarray technology, we have recently shown that the ADAM15 disintegrin is significantly overexpressed during the metastatic progression of human prostate cancer. 18281484 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE These data indicate that selective expression of ADAM-15 variants in breast cancers could play an important role in determining tumor aggressiveness by interplay with intracellular signaling pathways. 18296648 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE In conclusion, our results point to a physiological role of ADAM15 as a natural binding partner of integrin alphavbeta3 thereby loosening tumor cell adhesion to the underlying matrix and regulating tumor cell migration and invasion. 15618016 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 AlteredExpression group BEFREE ACs showed the strongest staining (tumor center; ADAM15ecto; mean+/-SEM; 5.47+/-1.04), whereas SCLCs only showed weak ADAM15 expression (2.67+/-0.42; SCCs: 3.62+/-0.62). 15756594 2005